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The design and structural optimisation of a novel polysaccharide-based nanomaterial for the 34 
controlled and sustained release of doxorubicin are here reported. A cross-linked polymer was 35 
obtained by reacting a tetraglucose, named cyclic nigerosyl-1-6-nigerose (CNN), with pyromellitic 36 
dianhydride. The cross-linking reaction formed solid nanoparticles, named nanosponges, able to 37 
swell as a function of the pH. Nanoparticle sizes were reduced using High Pressure 38 
Homogenization, to obtain uniform nanosuspensions. Doxorubicin was incorporated into the CNN-39 
nanosponges in a good extent. DSC and solid state NMR analyses proved the drug interaction with 40 
the polymer matrix. In vitro studies demonstrated pH-dependent slow and prolonged release 41 
kinetics of the drug from the nanoformulation.  Doxorubicin-loaded CNN-nanosponges were easily 42 
internalized in A2780 cell line. They might considered an intracellular doxorubicin reservoir, able 43 
to slowly release the drug over time. CNN-nanosponges may be promising biocompatible 44 
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1. Introduction 51 
Controlled and sustained release delivery systems of drugs may open up new avenues in 52 
nanotherapeutic fields to overcome some drug limitations, with spatial and time-controlled release 53 
kinetics (Arpicco et al., 2016, Prasad at al., 2018). A number of these formulations have used 54 
nanoscaled carriers encapsulation.  Indeed, drug delivery system-based nanoparticles, able to store 55 
and release molecules for an extended period of time (weeks or months) and as a function of an 56 
external stimulus, can play a key role in developing safer and more effective nanomedicines (Mura, 57 
Nicolas & Couvreur, 2013). The use of nanocarriers allows for the modulation and modification of 58 
the physico-chemical properties of drugs, producing improved pharmacokinetics and bio-59 
distribution profiles (Hamidi, Azadi, Rafiei & Ashrafi, 2013). Various biodegradable and 60 
biocompatible polymer systems could be used as interesting advanced controlled-release systems 61 
for bioactive molecules (Duchene, Cavalli & Gref, 2016). Polymer nanoparticles are easy to 62 
produce with improved stability and more control over drug release (Jaimes-Aguirre, et al., 2016). 63 
Indeed, drug release kinetics can be precisely controlled by the physico-chemical properties of the 64 
polymer, such as molecular weight, porosity, hydrophobicity and crystallinity (Bhattacharjee et al., 65 
2016). Moreover, the presence of specific moiety in the polymer structure, responsive to external 66 
stimuli, i.e. dissociable carboxylic groups or redox reactive groups, may facilitate localised drug 67 
delivery (Liu, Yang & Urban, 2017). 68 
Notably, prolonged-release polymer nanoparticles can reduce the frequency of administration of 69 
drugs, particularly those with a short half-life, stabilise drug absorption, decrease the occurrence of 70 
adverse side effects  and improve  patients' adherence to therapy (Natarajan, Nugraha, Ng & 71 
Venkatraman, 2014). In particular, poly(lactic-co-glycolic acid (PLGA), a biodegradable polyester 72 
approved for human use,  has been extensively studied to obtain sustained release nanovectors. 73 
Much attention in research has been focused on designing  PLGA nanosystems for the controlled 74 
delivery of anticancer drugs (Dinarvand, Sepehri, Manoochehri, Rouhani & Atyabi, 2011, Khan et 75 
al., 2016). A number of PLGA nanoparticles were studied for doxorubicin, tuning the formulation 76 
design  to obtain prolonged release kinetics. Doxorubicin-loaded  PLGA nanoparticles with the  77 
surface modified with poly(L-γ-glutamic acid) (γ-PGA) and finally conjugated with folic acid 78 
showed a release profile lasting over 7 days (Jaimes-Aguirre et al., 2017). 79 
Cross-linked polymer nanoparticles represent an alternative formulation approach. Recently, 80 
cyclodextrin-based nanosponges, hyper cross-linked cyclodextrin polymers, with sizes in the 81 
nanometer order of magnitude, have been designed as a drug delivery nanosystem (Trotta, Zanetti 82 
& Cavalli, 2012, Liang et al.,2013, Trotta, Dianzani, Caldera, Mognetti & Cavalli, 2014, Caldera, 83 
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Tannous, Cavalli, Zanetti & Trotta, 2017, Liang et al., 2017, Sherje, Dravyakar, Kadam, Jadhav, 84 
2017). Cyclodextrins are a class of cyclic glucopyranose oligomers with a characteristic toroidal 85 
shape that forms a well-defined truncated cone-shaped lipophilic cavity. Cyclodextrins are able to 86 
include compounds whose geometry and polarity are compatible with that of their cavity 87 
(Muankaew & Loftsson, 2018). Cyclodextrin-based nanosponges exhibited a superior inclusion 88 
capability than parent cyclodextrins. Indeed, they were able to incorporate many types of molecules, 89 
such as small molecules, macromolecules and gases (Trotta et al., 2014, Swaminathan et al., 2010a, 90 
Cavalli et al., 2010). The loaded molecules are generally delivered with a slow and prolonged 91 
release profile, according to the nanoparticle network structure. Indeed, the release can be 92 
influenced by the cross-linking ratio and the nature of the polymer mesh to obtain a sustained and 93 
controlled delivery (Swaminathan et al., 2010b, Torne, Ansari, Vavia, Trotta & Cavalli, 2010, Daga 94 
et al., 2016, Gigliotti et al., 2017). The incorporation and storage capability is strongly affected by 95 
the polymer nanostructure, as well as the presence of  many cyclodextrin cavities able to cooperate. 96 
To load hydrophilic or charged molecules, modifications of nanosponges were devised.  97 
Interestingly, the introduction of charged groups either in the nanostructure or on the surface of 98 
nanosponges enabled the production of further interaction sites for loading dissociable drugs 99 
(Lembo et al., 2013, Bastiancich et al., 2014). Based on these premises and to expand the possibility 100 
of controlling the release, another cyclic oligosaccharide. i.e. a tetraglucose, was selected as a 101 
building block of new nanosponges, in place of cyclodextrins (Wei, et al. 2015). Intriguingly, cyclic 102 
nigerosyl-1-6-nigerose, (CNN) is a non-reducing cyclic tetrasaccharide with a unique structure 103 
consisting of four D-glucopyranosyl molecules connected by alternate α-(1-3) and α-(1-6) 104 
glycosidic bonds (Fig. 1A).  CNN differs from cyclodextrin not only due to its number of glucose 105 
units (4) and type of glucosidic bond, but also due to the arrangement of the hydroxyl groups. 106 
Namely, two of them are oriented toward the inner cavity of CNN, making it quite polar.                     107 
This cyclic tetrasaccharide is obtained from hydrolysed starch by the action of a mixture of 108 
enzymes (Nishimoto et al., 2002, Aga et al., 2003). Cyclotetraglucose occurs naturally in sake lees 109 
(i.e., the sediment that forms during rice wine production), in sake itself and in food-grade starch 110 
(e.g., tapioca starch, cornstarch) (Watanabe et al., 2004). The industrial  manufacturing production 111 
is done by Hayashibara (Japan). This tetraglucose is a white crystalline powder which is safe and 112 
stable to temperature, while at alkaline pH values a slow degradation was observed (Weissenfeld, 113 
2005). The capacity to interact as such with various molecules was studied. The complexation of 114 
some aromatic compounds with CNN was investigated, showing the formation of guest-CN 115 
complexes with vanillin, cinnamaldehyde and eugenol (Ishikawa, Kuwano, Chaen & Matsumoto, 116 
5 
 
2009).  Moreover, CNN have been used for powdering tocopherol, vitamin D and EPA (Oku et al., 117 
2007). 118 
This work aims at exploiting the CNN unit as a monomer for the synthesis of new cross-linked 119 
polymers, called CNN-nanosponges (CNN-NS). To obtain the CNN-based polymer, a synthetic 120 
protocol was tuned, selecting pyromellitic dianhydride (PMDA) as a cross-linker (Figure 1B).  121 
Firstly, three types of CNN-NS will be considered varying the molar ratio between CNN and 122 
pyromellitic dianhydride (i.e. 1:2, 1:4, 1:6 ratios, respectively) to optimise the nanostructure for 123 
drug delivery. Their physico-chemical characterisation will be studied and the drug loading 124 
capability will be investigated using doxorubicin as the model molecule. Finally, the in vitro 125 
biological behaviour of doxorubicin-loaded CNN-NS will be evaluated. 126 
  127 
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2. Material and methods 128 
 129 
2.1 Materials 130 
Cyclic nigerosyl-1-6-nigerose (CNN) was received as a kind gift from Hayashibara (Japan). 131 
Doxorubicin hydrochloride and pyromellitic dianhydride (PMDA) were purchased from Sigma. 132 
Solvents and reagents, unless otherwise indicated, were analytical-grade commercial products, used 133 
as received.  134 
 135 
2.2 CNN-nanosponges synthesis 136 
The quantities of chemicals used for the synthesis of the three NS are listed in table 1. In summary, 137 
4.886 g of CNN, desiccated in an oven at 100°C up to constant weight, were solubilised in 20 mL 138 
of dimethyl sulfoxide (DMSO) at room temperature. Subsequently, 5 mL of triethylamine (Et3N) 139 
and, after a few minutes, the correct amount of pyromellitic dianhydride were added. The solution 140 
was vigorously stirred until gelation point was reached. The obtained monolithic block was then 141 
crushed, recovered by vacuum filtration, washed with an excess of deionised water and rinsed with 142 
acetone. After drying at room temperature, the powder was collected and further purified through 143 
Soxhlet extraction for 24 h with acetone. The scheme of the CNN-NS synthesis reaction is shown in 144 
figure 1B. 145 
 146 
Table 1. Quantities of chemicals used in the synthesis of the three types of CNN-NS 147 
 148 
 
DMSO CNN Et3N PMDA PMDA/CNN 
molar ratio (mL) (mmol) (g) (mmol) (mL) (mmol) (g) (mmol) 
CNN-NS 
(1:2) 
20.0 281.6 4.886 7.534 5.0 35.9 3.286 15.067 2 
CNN-NS 
(1:4) 
20.0 281.6 4.886 7.534 5.0 35.9 6.573 30.134 4 
CNN-NS 
(1:6) 







2.3 Swelling degree evaluation 153 
Dry CNN-NS specimens of known weights were immersed in buffer solutions with different pH 154 
values at room temperature (i.e. pH 2.0, pH 4.0, pH 6.0 and pH 7.4 disodium hydrogen 155 
phosphate/phosphoric acid buffer). At pre-determined time intervals, the swollen nanosponges were 156 
removed from the buffer, blotted with filter paper to absorb the excess surface solution and 157 
immediately weighed. The procedure was repeated until there was no further weight increase. The 158 
swelling degree (SD) was then calculated as follows: 159 
𝑆𝑆 =  
(𝑊𝑡 −  𝑊𝑑)
𝑊𝑑
 
where Wt is the weight of the swollen nanosponges and Wd is the weight of the nanosponges in the 160 
dry state.  All experiments were performed in triplicate.  161 
 162 
2.4 X-ray powder diffraction (XRPD) analysis 163 
To characterise the nanosponges, we carried out a detailed XRPD analysis using a Siemens D5000 164 
diffractometer (Cu Kα1, Bragg-Brentano geometry, sequential collection between 2.5° and 60° 2θ).  165 
The diffraction patterns were analysed using Fityk software (Wojdyr, 2010). 166 
 167 
2.5 DSC analysis 168 
Differential Scanning Calorimetry (DSC) was carried out by means of a Perkin Elmer DSC/7 169 
differential scanning calorimeter (Perkin-Elmer, CT-USA) equipped with a TAC 7 /DX instrument 170 
controller. The instrument was calibrated with indium for melting point and heat of fusion. A 171 
heating rate of 10°C/min was employed in the 25-250°C temperature range. Standard aluminium 172 
sample pans (Perkin-Elmer) were used; an empty pan was used as a reference standard. Analyses 173 
were performed in triplicate on 3 mg samples under nitrogen purge. 174 
 175 
2.6 Preparation of doxorubicin-loaded CNN-nanosponges (1:4) 176 
An aqueous suspension of the CNN-NS(1:4) at the concentration of 10 mg/ml was prepared. A pre-177 
homogenisation was carried out for 10 min of  Ultraturrax (Ika, Germany) at 24,000 rpm. The 178 
aqueous suspension was then transferred into a high pressure homogeniser (HPH) (Emulsiflex C5, 179 
Avestin, USA) and subjected to homogenisation. The protocol tuned consists of 5 cycles at 5,000 180 
psi for 5 min, 12 cycles at 7,000 for 90 min. The obtained aqueous nanosuspension was purified by 181 
dialysis and stored at 4°C. An aqueous solution of doxorubicine (2 mg/ml)  was incubated at room 182 
temperature with the CNN nanosuspension under mild stirring for 12 hours. Subsequently, a 183 
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dialysis step was performed to eliminate the unloaded doxorubicin. For cell experiments the 184 
nanosuspension was prepared in NaCl 0.9%  w/v aqueous solution.  185 
 186 
2.7 Quantitative determination of doxorubicin 187 
The quantitative determination of doxorubicin was carried out by a HPLC system consisting of a 188 
pump (LC-9A PUMP C, Shimadzu, Japan) equipped with a fluorescence detector (Chrompack, 189 
Japan). Analyses were performed using an Agilent TC C18 column (250 mm × 4.6 mm, 5 µm). The 190 
mobile phase was a mixture of 0.01 M KH2PO4 (pH 1.4), acetonitrile and methanol (65:25:10 191 
v/v/v), degassed and pumped through the column at a flow rate of 1 ml/min. The column effluent 192 
was monitored at excitation and emission wavelengths of 480 and 560 nm, respectively. The 193 
external standard method was used to calculate the drug concentration. For this purpose, 1 mg of 194 
doxorubicin was weighed, placed in a volumetric flask, and dissolved in water to obtain a stock 195 
standard solution. This solution was then diluted using the mobile phase, providing a series of 196 
calibration solutions, subsequently injected into the HPLC system. The linear calibration curve was 197 
obtained over the concentration range of 0.025−2.5 μg/ml with a regression coefficient of 0.999. 198 
 199 
2.8 Determination of doxorubicin  encapsulation efficiency 200 
A 10 mg/mL aqueous suspension of the freeze-dried loaded nanosponges was prepared using 201 
filtered water and doxorubicin extracted by sonication for 5 minutes at room temperature. After 202 
centrifugation, the drug concentration in the supernatant was determined by the HPLC method 203 
previously described. Encapsulation efficiency and drug loading were then calculated using the 204 
calibration curve.  205 
 206 
2.9 Size, polydispersity index and zeta potential values  207 
CNN-NS sizes and polydispersity indices were measured by dynamic light scattering using a 90 208 
Plus particle sizer (Brookhaven Instruments Corporation, USA) equipped with MAS OPTION 209 
particle sizing software. The measurements were made at a fixed angle of 90° for all samples, 210 
which were suitably diluted with filtered and distilled water for every measurement. The zeta 211 
potential measurements were also taken using an additional electrode in the same instrument. For 212 
zeta potential determination, samples of the three formulations were diluted with 0.1 mM KCl and 213 
placed in the electrophoretic cell, where an electric field of about 15 V/cm was applied. 214 
 215 
2.10 Solid state NMR analysis  216 
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Solid state NMR spectra were acquired using a Jeol ECZR 600 instrument, operating at 600.17 and 217 
150.91 MHz for 1H and 13C nuclei, respectively. Powder samples were packed into cylindrical 218 
zirconia rotors with a 3.2 mm OD and a 60 µL volume. A certain amount of sample was collected 219 
from each batch and used without further preparations to fill the rotor. 13C CPMAS spectra were 220 
acquired at a spinning rate of 20 kHz using a ramp cross-polarisation pulse sequence with a contact 221 
time of 3.5 ms, a 90° 1H pulse of 2.189 µs, (optimised) recycle delays of 3.5 s (doxorubicin), 1.9s 222 
(blank CNN-NS (1:4)) and 0.4s (doxorubicin-loaded CNN-NS(1:4)) and a number of scans 223 
included between 2000 and 10000, depending on the sample. For every spectrum a two pulse phase 224 
modulation (TPPM) decoupling scheme was used, with a radiofrequency field of 108.5 kHz. The 225 
chemical shift scale was calibrated through the methylenic signal of external standard glycine (at 226 
43.7 ppm). 227 
 228 
2.11 Morphology analysis 229 
Transmission electron microscopy (TEM) was used to evaluate particle shape and morphology. A 230 
Philips CM 10 transmission electron microscope was used and the particle size was measured using 231 
the NIH image software. The nanosponge suspensions were sprayed on Formwar-coated copper 232 
grid and air-dried before observation. 233 
Scanning electron microscopy (SEM) was used to evaluate the morphology of the CNN-NS  234 
formulations using a JEOL JSM IT300LV (EHT 20 kV, working distance 10 mm). The 235 
nanosponges were positioned on a conductive sample holder and sputtered with graphite to assure 236 
the conductivity of the sample.  237 
 238 
2.12 ATR FTIR analysis 239 
ATR FTIR analysis was applied to doxorubicin-loaded CNN-NS, free doxorubicin and plain CNN-240 
NS using a Perkin Elmer 2000 instrument. The spectra were recorded between 400 and 4000 cm-1. 241 
 242 
2.13 Stability evaluation of CNN-nanosponges 243 
The physical stability of CNN-NS was evaluated over time, determining size, surface charge and 244 
doxorubicin loading, as previously described. This thermal stability of CNN-NS  can allow for 245 
sterilisation by autoclaving for cell experiments. 246 
 247 
2.14 In vitro release of doxorubicin  from CNN-nanosponges (1:4)  248 
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The in vitro release was carried out using multi-compartment rotating cells with a dialysis  249 
membrane (Sartorius, cut off 12,000 Da). The donor phase consisted of nanosponge formulation 250 
containing a fixed amount of doxorubicin in phosphate buffer at pH 7.4 (1 ml). The receiving phase 251 
consisted of phosphate buffer, pH 7.4 or pH 5.5 added with 0.5% w/v sodium lauryl sulphate (1 ml) 252 
to maintain proper sink conditions. The receiving phase was completely withdrawn and replaced 253 
with fresh medium after fixed time intervals, suitably diluted and analysed using the HPLC method 254 
described above.  255 
 256 
2.15 Biological assays  257 
 258 
2.15.1 Haemolytic activity of CNN-nanosponges 259 
CNN-NS (10 mg/mL) were incubated at 37°C for 90 minutes with 1 ml of diluted blood. Freshly 260 
prepared PBS (pH 7.4) was used for all dilution purposes. After incubation, blood-containing 261 
suspensions were centrifuged at 2,000 rpm for 10 min to separate the plasma. The amount of 262 
haemoglobin released due to haemolysis was measured spectrophotometrically at 543 nm (Du 730, 263 
Beckman). The haemolytic activity was calculated with reference to blank and complete 264 
haemolysed samples (induced by the addition of ammonium sulphate 20% w/v). Optical 265 
microscopy was also used to see if there were any abnormalities in the blood cells after incubation. 266 
The observations were made with reference to the blank diluted blood. No changes in red blood cell 267 
morphology were detected.  268 
 269 
2.15.2 In vitro cytotoxicity determination 270 
The ovarian cell line, A2780, was obtained from the American Type Culture Collection (Rockville, 271 
MD, USA). The cells were grown as a monolayer culture in RPMI 1640 medium supplemented 272 
with 10% heat-inactivated fetal calf serum (FCS), 2 mmol/l L-glutamine and 273 
penicillin/streptomycin (100 units/ml), at 37°C in 5% CO2 humidified atmosphere.   274 
 275 
2.15.3 Colony-forming assay 276 
Cells (1,000 per well) were seeded into six-well plates and treated with the compounds. The 277 
medium was changed after 72 h and cells were cultured for an additional 10 days without any drug. 278 
Subsequently, the cells were fixed and stained with a solution of 80% crystal violet (Sigma-Aldrich) 279 
and 20% methanol for 30 min. The cells were then perfectly washed and 30% acetic acid was added 280 
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to induce a complete dissolution of the crystal violet. Absorbance was recorded at 595 nm by a 96-281 
well-plate ELISA reader. Five different experiments were performed. 282 
  283 
2.15.4 In vitro uptake study 284 
5 x 104 cell/well of A2780 cells were seeded in 24-well plates in 1 ml of culture medium and treated 285 
with 10-7 M free Doxorubicin or CNN Doxorubicin. 48 h  (T48) later the cells cultured on the 286 
coverslips were rinsed three times with cold PBS and fixed with 75% ethanol for 30 min at 4°C and 287 
the coverslips were inverted and mounted on glass slides. The nuclei were stained with 4′,6′- 288 
diamidino-2-phenylindole (DAPI 1 mg·mL-1; Sigma-Aldrich, Saint Louis, MO, USA). The slides 289 
were analysed by confocal laser scanning microscopy (CLSM) using a Leica DMIRE2 confocal 290 
fluorescence microscope (Leica Microsystems AG, Wetzlad, Germany) equipped with Leica 291 
Confocal Software v. 2.61.  292 
 293 
2.16. Statistical analysis 294 
Data are shown as mean ± SEM. Statistical analyses were performed with GraphPad Prism 3.0 295 
software (La Jolla, CA, USA) using one-way ANOVA and Dunnett’s test. Values of P <0.05 were 296 
considered statistically significant. 297 
 298 
  299 
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3. Results and Discussion 300 
One strategy to improve the therapeutic effectiveness and to reduce the side effects of anticancer 301 
drugs on healthy cells is to improve local drug concentrations at the disease tissues. Biocompatible 302 
nanoparticles containing drugs can provide a site-specific delivery of anticancer drugs in a 303 
controlled and sustained manner improving the safety profile (Brigger, Dubernet & Couvreur, 304 
2002). Nanoscaled delivery systems can carry loaded drugs to the tumour site through the 305 
bloodstream, taking advantage of the enhanced permeability and retention (EPR) effect, due to the 306 
defective vascular architecture of the tumour (Fang, Nakamura & Maeda, 2011, Maeda, Nakamura 307 
& Fang, 2013). Stimuli-responsive polymer nanoparticles can allow more precise and controlled 308 
release behaviour (Cheng, Meng, Deng, Klok & Zhong, 2013). Based upon these concepts, a new 309 
nanodelivery system has been developed, using  a biocompatible tetraglucose, i.e. cyclic nigerosyl-310 
1-6-nigerose (CNN), as an innovative building block. Solid cross-linked polymer nanoparticles, 311 
named cyclic nigerosyl-1-6-nigerose based nanosponges (CNN-NS) were prepared, by the reaction 312 
of CNN with pyromellitic dianhydride, to obtain pH resposiveness. Figure 1B reports the schematic 313 





Figure 1. A) Chemical structure of cyclotetraglucose (CNN)    B) Scheme of the CNN-NS 317 
synthesis reaction C) ATR-FTIR spectra of CNN and CNN-NS D) Swelling capacity of CNN-NS 318 
(1:2) as a function of  pH values (pH 2 and 7.4). 319 
 320 
PMDA was selected, among several cross-linkers, for its high reactivity towards hydroxyl groups, 321 
which allows fast reactions with high yields and because of the interactions that carboxylic groups 322 
of pyromellitic bridges may establish with polar moieties of drugs (i.e. -COOH, -NH2, -OH 323 
groups). These interactions might contribute to high encapsulation efficiency and slow release 324 
kinetics. Moreover, the high content of carboxylic groups, introduced by PMDA, confers a pH-325 
sensitive character to CNN-NS, which may be profitably exploited to modulate the release of 326 
loaded drugs. The presence of the cross-linked network was confirmed by FTIR analysis. Indeed, 327 
the absorption band typical of carboxylate groups appeared in the FTIR-ATR spectrum of CNN-NS 328 
at 1580 cm-1, along with other signals deriving from pyromellitic units (i.e. C=O stretching in 329 
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carboxylic groups at 1720 cm-1 and C-O stretching in ester groups at 1240 cm-1, approximately) was 330 
not detected in the spectrum of pristine CNN (figure 1C).  331 
The synthetic process is one-step, cost-effective and its repeatability and scalability have been 332 
confirmed. After synthesis, the solid CNN-NS underwent to the HPH step to decrease the 333 
nanoparticle dimensions and to produce smaller sizes and more uniform distribution. Indeed, the 334 
CNN-NS sizes were reduced reaching sizes lower than 400 nm. 335 
Here, the optimisation and in vitro characterisation of this new tetraglucose-based nanodelivery 336 
system are reported.  Firstly, the effect of the three different CNN cross-linker ratios (i.e. 1:2, 1:4 337 
and 1:6) on the nanostructue and physico-chemical properties was investigated to characterise the 338 
three products.  All the obtained CNN-NS are amorphous solids, although CNN as such is markedly 339 
crystalline. Figure 2 shows the XRPD diagrams of the three types of CNN-NS compared with that 340 






Figure 2. X-ray powder diffraction patterns of the CNN-NS obtained by reacting the CNN with 345 
variable concentrations of pyromellityc dianhydride (1:2, 1:4, 1:6 respectively) compared with the 346 
XRPD of the nigerose (bottom). 347 
 348 
Despite the high degree of crystallinity displayed by nigerose, CNN-NS highlight their amorphous 349 
behaviour, shown by the broad bump in the range 10-40 °2θ. 350 
The amorphous nature was confirmed by DSC analyses. No peaks correlated to thermal changes 351 
were observed until 250°C (data not shown). 352 
CNN-NS were easily able to absorb water and their swelling capacity was investigated as a function 353 
of the pH value of the external environment. 354 
The three types of CNN-NS showed a marked swelling capacity related to the cross-linking degree, 355 
which remarkably depends on the pH value (Table 2). 356 
Interestingly, CNN-NS were pH sensitive due to the presence of dissociable carboxylic groups in 357 
the polymer matrices. In particular, the swelling degree of the three types of nanosponges linearly 358 
increased  from pH 2.0 to pH 7.4.  359 
Table 2 reports the swelling degree of the two nanosponges as a function of  pH values of the 360 
external medium.  361 
 362 
Table 2. Swelling degree of CNN-NS as a function of  pH values of the external medium. 363 
Sample 
Swelling degree (%) 
pH 2.0 pH 4.0 pH 6.0 pH 7.4 
CNN-NS (1:2) 562 680 765 820 
CNN-NS (1:4) 124 215 307 415 
CNN-NS (1:6) 88 206 248 392 
 364 
It can be seen that CNN-NS (1:2) demonstrated a higher water uptake capability at all the pH values 365 
than those of the other two CNN-NS with higher degrees of cross-linking (Figure 1D). 366 
Indeed, the lower the cross-linking degree, the higher the observed swelling. Interestingly, CNN-NS 367 
can be considered a quasi super-absorbent material, that was able to retain more than 800 wt% of 368 
water at room temperature and pH 7.4.  369 
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In this work, doxorubicin was selected as a model drug. Doxorubicin is one of the most common 370 
anticancer drug, but it suffers of severe side effects and multidrug resistance. Therefore a 371 
nanoformulation to improve its pharmacokinetics and biodistribution would be valuable. 372 
Preliminary explorative experiments proved that CNN-NS (1:4) were the most suitable for loading 373 
and storing doxorubicin. As a consequence, this type of CNN-NS was selected for further 374 
investigation and characterization with the drug. 375 
Table 3 reports the physico-chemical characterization of doxorubicin-loaded and unloaded CNN-376 
















Average diameter  ± SD 
(nm) 
355.6 ± 27.3 360.8 ± 15.6 
PDI 0.20 ± 0.02 0.19 ± 0.03 
PZ ± SD 
(mV) 
- 30.2 ± 4.55 - 29.2 ± 5.29 





Doxorubicin encapsulation in CNN-NS did not require high-energy processes or solvent use 389 
preserving the drug from potential degradation. Interestingly, it is incorporated by incubation at 390 
room temperature under mild stirring. Doxorubicin is a hydrophilic drug with a good aqueous 391 
solubility (10 mg/ml).  The hydrophilicity of the polymer mesh and probably the polarity of the 392 
CNN cavity provide drug encapsulation with high efficiency. The polymer network should play the 393 
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key role in the drug incorporation. Indeed, the CNN monomer possesses only a shallow saucer-like 394 
shape with a small concave at the center, confirmed by X-ray crystallographic analysis (Bradbrook 395 
et al., 2000, Yang et al., 2012). Considering this CNN architecture, the doxorubicin might be mainly 396 
entrapped in the hydrophilic nanochannels of the polymer network. The drug loading was 15.5% for 397 
doxorubicin-loaded CNN-NS (1:4), with an encapsulation efficiency of about 95%. 398 
Figure 3 shows the SEM (A) and TEM (B) images of CNN-NS before and after HPH step 399 
respectively.  400 
 401 
 402 
Figure 3. A) SEM image of CNN-NS before HPH step and B) TEM image of the CNN-NS after 403 
HPH step (TEM scale bar 300 nm).  404 
 405 
Figure 3A shows the irregular morphology and large particle size of NS prior to HPH treatment. 406 
As reported in the literature (Trotta, 2011), dextrin-based NS have generally rather compact 407 
structures. Also in the case of CNN-NS, BET analysis revealed surface area values below 2 m2/g 408 
(data not shown). Cyclodextrin- and CNN-NS have nanometric and sub-nanometric intrinsic 409 
porosity, deriving from the inner cavities of dextrin monomers and from the interstitial volumes 410 
among dextrin monomers. Such molecular-level porosity cannot be discerned by means of scanning 411 
electron microscopy.  TEM image (Fig. 3B) shows the CNN-NS spherical shape and confirms the 412 
nanoscaled sizes, reached after the homogenization process. 413 
When loaded with doxorubicin, CNN-NS lose their frankly amorphous behaviour, increasing their 414 
low range ordering. Indeed, the new order does not tally with the structure of crystalline 415 
doxorubicin, as shown in Figure 4A. The presence of a few broad diffraction peaks in the 416 
diffraction pattern of the loaded CNN-NS demonstrates the formation of a brand new, poorly 417 
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Figure 4. A) CNN-NS (1:4) loading with doxorubicin leads to a deep modification of the 423 
nanosponge diffraction pattern (doxorubicin-loaded CNN-NS (1:4) in figure) B) Experimental data 424 
(dots) and calculated function (red curve) of XRPD of the doxorubicin-loaded CNN-NS. Broad 425 
yellow curves represent the decomposition of the XRPD pattern, while the blue one corresponds to 426 
the amorphous background. 427 
 428 
Table 4: Position, height, area and full width at half maximum of the three diffraction peaks of the 429 










1 21.3426 37.5097 478.982 11.9962 
2 36.6454 23.6005 60.563 2.41077 







The diffraction data of the CNN 1:4 nanosponges with doxorubicin were decomposed using the 436 
Fityk software (Wojdyr, 2010). The decomposition of the XRPD pattern shows at least three curves 437 
representing the poor ordering of the system. 438 
Due to the broad behaviour of the peaks, a Gaussian profile fitting was selected. The pattern shows 439 
a bump (blue line in Figure 4B) ascribable to the amorphous phase and three broad peaks (yellow) 440 
possibly related to the weak ordering of the doxorubicin in the loaded nanosponge. 441 
DSC analysis  of  doxorubicin-loaded CNN-NS  showed  the drug incorporation in the nanosponge 442 
matrix (Figure 5A). Indeed, the endothermic peak related to the melting of doxorubicin at about 443 
220°C is missing in the thermograms of doxorubicin-loaded CNN-NS, indicating that the drug is 444 
molecularly dispersed in the polymer matrix. 445 
The cross-linked structure of CNN-NS was confirmed by 13C solid state NMR analysis. Signals 446 
deriving from carbonyl groups in ester/carboxylic moieties and aromatic carbon atoms belonging to 447 
PMDA units appear at approximately 170 and 130 ppm, respectively (figure 5B). 448 




Figure 5. A) DSC thermograms of CNN-NS (1:4), free doxorubicin and doxorubicin-loaded CNN-451 
NS B) Solid NMR profiles of CNN-NS (1:4), free doxorubicin and CNN-NS. C) Comparison 452 
between 13C CPMAS spectra of doxorubicin, blank nanosponge and doxorubicin-loaded CNN-NS 453 






Figure 5b shows the 13C CPMAS SSNMR spectra of doxorubicin, blank CNN-NS (1:4) and 458 
doxorubicin-loaded CNN-NS (1:4). Figure 5c shows the comparison between the spectra of the 459 
three samples. In the spectrum of the loaded sample (doxorubicin-loaded CNN-NS, red) several 460 
signals, different from the characteristic peaks of the CNN-NS (blank nanosponges, blue), are 461 
observed and indicated with arrows. These signals are compliant with the typical chemical shifts of 462 
the 13C atoms of doxorubicin (also shown in the figure) and thus evidence the presence of 463 
doxorubicin inside the nanosponges. 464 
Then, the in vitro doxorubicin release kinetics from CNN-NS was evaluated at pH 5.5 and at pH 7.4 465 




Figure 6. A) In vitro release kinetics of doxorubicin from CNN-NS (1:4) as a function of pH; B)  In 470 
vitro release kinetics of doxorubicin from CNN-NS (1:4) at pH = 7.4 471 
 472 
In vitro release profiles showed a very slow and constant release of the drug over time depending on 473 
the pH value of the receiving phase. Interestingly, no burst effect was observed at both pH values. 474 
After 24 hours only 1.3% of doxorubicin was released from CNN-NS at pH 7.4, while the 475 
percentage of doxorubicin released at pH 5.5 reached 10%. The slow and pH-sensitive release 476 
profile may be related to the chemical structure of CNN-NS. The main role is played by the 477 
polymer matrix, which comprises free carboxylic groups in the polymer network. The carboxylic 478 
groups, belonging from the pyromellitic dianhydride used as cross-linker, are only partially 479 
dissociated at pH 5.5 resulting in lower interactions and favouring the drug release. On the other 480 
hand, the cavity of CNN monomer is not suitable for doxorubicin complexation being a very small 481 
pocket, as previously reported. Considering the β-cyclodextrin-based NS obtained by reacting β-CD 482 
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with pyromellitic dianhydride, a doxorubicin release of about 10% was reached after 6 hours at pH 483 
7.4 (data not shown). This different behaviour might be related to the narrow polymer meshes 484 
present in CNN-NS. Indeed, the extremely slow and prolonged release behaviour from CNN-NS 485 
compared to other doxorubicin nanosponge formulations at pH 7.4 (Cavalli, Trotta & Tumiatti, 486 
2006) might represent an advantage to limit the drug blood exposure and the toxicity of 487 
doxorubicin. 488 
We speculate that doxorubicin may be released in a controlled manner following Fickian kinetics 489 
due to drug diffusion through the polymeric matrix, which underwent degradation with a very slow 490 
kinetics due to hydrolysis. Indeed, the absence of any burst effect could indicate that doxorubicin is 491 
not adsorbed on the nanosponge surface and CNN-NS are slowly degraded in the physiological 492 
environment. 493 
The release mechanism was further evaluated. The doxorubicin in vitro release from drug-loaded 494 
CNN-NS was fitted to four distinct models to determine which one exhibited the highest correlation 495 
with the experimental results. For each model, the rate constant and correlation values were 496 
obtained by applying a linear regression fit. The zero-order kinetic model demonstrated the higher 497 
correlation, showing R2 values of 0.9969 and 0.9985 for doxorubicin release at pH 7.4 and pH 5.5, 498 
respectively. 499 
The in vitro release kinetics of doxorubicin from CNN-NS at pH 7.4 was followed up to 21 days 500 
(Figure 6B). 501 
Intriguingly, the results indicate that at physiological pH value, CNN-NS provide a slow drug 502 
diffusion and controlled release over a lengthy period. Indeed, after 14 days at pH 7.4 only about 503 
20% of the drug was released and after 21 days this reached about 32.5%.  This behaviour could be 504 
exploited to obtain a constant drug concentration in tumour tissue in loco-regional treatment (Cheng 505 
et al., 2017, Cinar et al., 2017). Interestingly, the tumour environment pH is more acid than that of 506 
normal tissue (Manchun, Dass & Sriamornsak, 2012). 507 
In order to verify the absence of nanosponge activity, cells were treated with plain CNN-NS at 508 
dilutions corresponding to that drug-loaded CNN-NS. In all the concentrations tested, the results 509 
overlapped with those obtained in controls, with no significant inhibition of cell proliferation, thus 510 
excluding any toxic effect of the nanocarriers. 511 
Concerning CNN-NS safety, no significant hemolysis caused  by CNN-NS either blank or 512 
doxorubicin loaded was observed, confirming their good biocompatibility and the presence of 513 
tonicity values suitable for a future potential in vivo administration. 514 
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Clonogenic survival assays were performed. The cells were seeded 6-well plates and treated with 515 
each compound. The culture medium was changed after 72 h, and the cells were cultured for an 516 
additional 10 days in the absence of the compounds. The results showed that doxorubicin or CNN 517 
doxorubicin treatments differently inhibited the ability of the A2780 cell line to form colonies. In 518 
fact, both formulations induced the maximum effect at 10-7M, but doxorubicin-loaded CNN-NS 519 
were able to induce a higher inhibition of the colony formation at 10-8-10-9M, determining growth 520 
inhibition around 80% and 50%, respectively. Conversely, the treatment with doxorubicin in 521 
solution produced a smaller inhibition of the ability to form colonies (50%) at 10-8 M, being no 522 




Figure 7. Effect of doxorubicin and doxorubicin-loaded CNN-NS on cell clonogenicity was tested 527 
by colony forming assay. A2780 cells (1000 per well) were seeded in six-well plates and treated 528 
with each drug at the indicated concentrations for 72 h. The medium was then changed and cells 529 
were cultured for additional 10 days and subsequently fixed and stained with crystal violet. Data 530 
shown are means ±SEM (n = 5). **P < 0.01, *P < 0.05 significantly different from the same 531 




Indeed, the IC50 was 0.9±0.2 x 10-9M and 8.5±1 x 10-9M, respectively for doxorubicin-loaded 534 
CNN-NS and for free doxorubicin. Therefore, the cytotoxicity of doxorubicin loaded in 535 
nanosponges was enhanced of about 8 fold than free drug on A2780 cell lines.  536 
Cell uptake is promoted by nanocarriers as previously shown with various nanoformulations 537 
(Miglietta, Cavalli, Bocca, Gabriel & Gasco, 2000, Ernsting, Murakami, Roy, & Li, 2013, Wang et 538 
al., 2016). The size, surface charge and the components of CNN-NS might favored the cell 539 
internalization. Indeed, in vitro uptake results demonstrated that fluorescence was localized in the 540 
cytoplasm around the nucleus to a greater extent in the cells treated with doxorubicin-loaded CNN-541 
NS, indicating that CNN-NS had been internalised in a greater extent into the cells. 542 
 543 
 544 
Figure 8.  Cell uptake was evaluated by fluorescence microscopy analysis using different doses of 545 
doxorubicin-loaded CNN-NS (DOXO-CNN) o free DOX on A2780 cells for 48 h.  546 
 547 
Clonogenic assay or colony formation assay is an in vitro cell survival assay based on the ability of 548 
a single cell to grow into a colony. Only a fraction of seeded cells retains the capacity to produce 549 
colonies. After plating at very low density (800 cells for wells), cells are treated with the 550 
compounds for 72h, thus they were washed with the cell medium, to remove drugs, and were then 551 
allowed to grow over an extended period of time (10 days). Doxorubicin-loaded CNN-NS may act 552 
as intracellular drug reservoir slowly releasing the free drug into the cellular cytoplasm, enhancing 553 
its therapeutic efficacy. Doxorubicin encapsulation in CNN-NS might increase its concentration at 554 
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the tumor site, thereby decreasing the frequent dose administered and subsequently reducing the 555 
side effects. In this in vitro assay, free DOX is also able to inhibit the colony formation, especially 556 
at the highest concentration tested (10-7M), considering the static conditions of the experimental set-557 
up. We can hypothesize a different behaviour in vivo. Various factors controlled the 558 
pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles after their in vivo 559 
administration (Ernsting et al., 2013). A crucial role is played by the EPR effect, that allows the 560 
nanoparticles to escape from the vessels and enter in the tumor cells. 561 
 562 
4. Conclusions 563 
A new polymer-based nanomaterial was obtained, exploiting a tetraglucose, i.e. CNN, as a 564 
monomer in the synthetic reaction. The cross-linking reaction with pyromellitic dianhydride formed 565 
solid nanoparticles, named nanosponges. This new nanomaterial is biocompatible and is able to 566 
swell in response to the pH value. CNN-NScan be formulated as nanoscale particles with spherical 567 
shape suitable for drug delivery. Doxorubicin was incorporated in a good extent and released with a 568 
very slow and constant kinetics. Interestingly, the environment pH play a role in controlling the 569 
release profile of the drug. 570 
Based on the results, doxorubicin-loaded CNN-NS might act as a nanomedicine tool for tumor local 571 
treatment with a favorable toxicology profile. 572 
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